Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Gastric Cancer
Interventions
DRUG

TS-1 and cisplatin

TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.

DRUG

TS-1

TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.

Trial Locations (1)

Unknown

East Hospital, Kitasato University, 2-1-1, Asamizodai, Sagamihara

All Listed Sponsors
lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT00150670 - Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter